A hazard ratio of 0.53 is not a marginal result — it represents a 47% reduction in the risk of progression or death, achieved in a population where median progression-free survival on best supportive care was just 2.8 months. That baseline figure is the real context for the TEDOVA trial: patients with platinum-sensitive recurrent ovarian cancer who had already exhausted PARP inhibitors and bevacizumab, a corner of the disease where meaningful intervention has been essentially absent for years.
The TEDOVA Phase 2 enrolled 185 patients randomized across three arms — best supportive care, Tedopi monotherapy, and Tedopi plus pembrolizumab — with the primary endpoint comparing the combination against control. The combination arm hit statistical significance (p<0.001), pushing median PFS to 4.1 months versus 2.8 months. That absolute gain looks modest in isolation, but the hazard ratio tells a different story about the shape of the survival curves, and in a chemotherapy-exhausted setting this is a genuine signal. The monotherapy arm also showed activity; the combination beat monotherapy with an HR of 0.72, though that comparison fell short of significance at p=0.074. The distinction matters because it raises a real mechanistic question: how much of the benefit is vaccine-driven versus checkpoint-driven, and whether the two are genuinely synergistic or additive.
Tedopi is a neoepitope therapeutic vaccine targeting HLA-A2-positive patients through multi-peptide T-cell priming. Its earlier Phase 3 data in non-small cell lung cancersmall cell lung cancer — specifically in HLA-A2-positive patients who had progressed on checkpoint inhibitors — showed OS benefit in a pre-specified subgroup, which is what brought it this far. TEDOVA now extends proof-of-concept to ovarian cancer, a tumor type historically considered immunologically cold and where checkpoint monotherapy has largely failed. The combination with pembrolizumab producing a clear PFS benefit in this context implies that Tedopi’s T-cell priming may be sufficient to render the tumor microenvironment responsive to PD-1 blockade — a mechanistic argument with implications well beyond this trial.
The one endpoint to watch when full data are presented at ASCO on May 30 is the HLA-A2 subgroup analysis. Tedopi’s mechanism is HLA-restricted, and if the PFS benefit concentrates in HLA-A2-positive patients — as it did in lung cancer — that would sharpen the patient selection rationale dramatically and set a more credible foundation for any Phase 3 design in ovarian cancer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
